A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines

Anti-Cancer Drugs

Volumn 8, Issue 7, 1997, Pages 686-695

  Nio, Yoshinori ^a   Ohmori, Hiroshi ^a   Minari, Yoshimitsu ^a   Hirahara, Noriyuki ^a   Sasaki, Susumu ^a   Takamura, Michio ^a   Tamura, Katsuhiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Pancreatic cancer; Vesnarinone

Indexed keywords

PIPERANOMETOZINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; HUMANS; LAMININ; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEOGLYCANS; QUINOLINES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030773462     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708000-00007     Document Type: Article

References (27)

1. Janes RH Jr, Niederhuber JE, Chmiel SJ, et al. National patterns of care for pancreatic cancer; results of survey on the Commission on Cancer. Ann Surg 1996; 223: 261-72.
2. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC, Chemotherapy prolongs survival inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
3. OPC-8212 Mulicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 1990; 4: 419-20.
4. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients. N Engl J Med 1993; 329: 149-55.
5. Sato S, Tomoyasu S, Okabe-Kado J, et al. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol 1996; 24: 37-42.
6. Nakai S, Kawai K, Aihara K, Adachi M. Antitumor effect of vesnarinone on leukemias and solid tumors by induction of cellular differentiation and apoptosis. Biotherapy 1995; 9: 889-97.
7. Sato M, Harada K, Bando T, et al. Characteristics of antitumor activity of 4-dihydro-6-[4-(3,4-dimethoxy-benzoyl)-1-piperazinyl]-2(1H)-quinorinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett 1995; 91: 1-9.
8. Koide T, Komatsu T, Yamazaki N, Yamamoto A, Ishihara K. Anti-tumor effect of DTIC with or without vesnarinone on the growth of human malignant melanoma (SK-14) in nude mice. J BCG BRM Ther 1995; 19: 39-50.
9. Lieber M, Mazzetta J, Nelson-Ress W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975; 15: 741-7.
10. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977; 19: 218-35.
11. Tan MH, Nowak NJ, Loor RM, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest 1986; 4: 15-23.
12. Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986; 17: 259-63.
13. Abrams JM, White K, Fesseler LI, Steller H. Programmed cell death during drosophila embryogenesis. Development 1993; 117: 29-43.
14. y antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993; 3: 381-90.
15. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
16. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V. Use of reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 1986; 83: 465-9.
17. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
18. Ovejera AA, Houchens DP, Baker AD. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 1978; 8: 50-6.
19. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. Effect of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 1992; 52: 6200-8.
20. Maruyama I, Maruyama Y, Nakajima T, et al. Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem Biophys Res Commun 1993; 195: 1264-71.
21. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
22. Nagata S, Goldstein P. The fas death factor. Science 1995; 267: 1449-56.
23. Levine B, Kalman J, Mayer L, Fiilit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 1990; 323: 236-41.
24. Repesh LA, Drake SR, Warner MC, et al. Adriamycin-induced inhibition of melanoma cell invasion is correlated with decrease in tumor cell motility and increases in focal contact formation. Clin Exp Metastasis 1993; 11: 91-102.
25. Harada K, Sato M. Induction of TGF-β on human salivary adenosquamous carcinoma cell line with vesnarinone. Biotherapy 1996; 41: 416-8.
26. Yoshinaka Y, Katoh I, Kyushiki H, Sakamoto Y. Alteration of the cytoskeletal organization in tumor cell line by a cardiac drug, vesnarinone, through protein tyrosine phosphorylation. Exp Cell Res 1995; 219: 21-8.
27. Imai S, Nio Y, Shiraishi T, Manabe T, Tobe T. In vivo inhibitory effect of anticancer agents on human pancreatic cancer xenografts transplanted in nude mice. Anticancer Res 1991; 11: 657-64.